Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells
Authors:
- Maria P.A. van BerkelMBMaria P.A. van Berkel
- Josephine C. DorsmanJDJosephine C. Dorsman
- Davy A.P. RockxDRDavy A.P. Rockx
- Herbert M. PinedoHPHerbert M. Pinedo
- Epie BovenEBEpie Boven
- 1 July 2007
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 74 (2) , 191-201
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylasesBiochemical and Biophysical Research Communications, 2005
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and Biophysical Research Communications, 2005
- Phosphorylation-Dependent Degradation of p300 by Doxorubicin-Activated p38 Mitogen-Activated Protein Kinase in Cardiac CellsMolecular and Cellular Biology, 2005
- Role of CBP in regulating HIF-1-mediated activation of transcriptionJournal of Cell Science, 2005
- DNA Damage Is a Prerequisite for p53-Mediated Proteasomal Degradation of HIF-1α in Hypoxic Cells and Downregulation of the Hypoxia Marker Carbonic Anhydrase IXMolecular and Cellular Biology, 2004
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- MAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300Journal of Biological Chemistry, 2003
- Time-Dependent Changes in Factors Involved in the Apoptotic Process in Human Ovarian Cancer Cells as a Response to CisplatinGynecologic Oncology, 2002
- HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor ExpressionMolecular and Cellular Biology, 2001
- Rac1 Activity Is Required for the Activation of Hypoxia-inducible Factor 1Journal of Biological Chemistry, 2001